Checkpoint Therapeutics 报告第一季度亏损，但在正在进行的癌症治疗开发中，股票略有上涨。 Checkpoint Therapeutics reports Q1 loss, yet stock rises slightly amid ongoing cancer treatment development.

检查点治疗研究所报告说,第一季度损失了每股0.69美元,缺少分析员的估计数。 Checkpoint Therapeutics reported a first-quarter loss of $0.69 per share, missing analysts' estimates. 尽管损失了,但公司库存略有增加,增至4.04美元。 Despite the loss, the company's stock increased slightly to $4.04. 检查点治疗正在开发固体瘤癌症的治疗方法, 其主要产品正在第一阶段试验中. Checkpoint Therapeutics is developing treatments for solid tumor cancers, with its lead product in Phase 1 trials. 来自各公司的分析师保持了他们的“买”和“控股”评级,其价格目标高于目前的股价。 Analysts from various firms have maintained their "buy" and "hold" ratings, with price targets set above the current stock price.